{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:53Z","timestamp":1763017613344},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T00:00:00Z","timestamp":1450915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12185-015-1922-x","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T05:19:47Z","timestamp":1450934387000},"page":"299-305","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases"],"prefix":"10.1007","volume":"103","author":[{"given":"Nobuhiro","family":"Tsukada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumito","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohsuke","family":"Meshitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Yoshiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,24]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u201396.","journal-title":"N Engl J Med"},{"key":"1922_CR2","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","volume":"121","author":"G Merlini","year":"2013","unstructured":"Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124\u201330.","journal-title":"Blood"},{"key":"1922_CR3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"1922_CR4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766\u20139.","journal-title":"Br J Haematol"},{"key":"1922_CR5","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","volume":"103","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960\u20133.","journal-title":"Blood"},{"key":"1922_CR6","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","volume":"19","author":"A Dispenzieri","year":"2001","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson S, Rajkumar V, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350\u20136.","journal-title":"J Clin Oncol"},{"key":"1922_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","volume":"140","author":"AD Wechalekar","year":"2008","unstructured":"Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008;140:365\u201377.","journal-title":"Br J Haematol"},{"key":"1922_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"1922_CR9","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","volume":"99","author":"RL Comenzo","year":"2002","unstructured":"Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276\u201382.","journal-title":"Blood"},{"key":"1922_CR10","first-page":"1635","volume":"91","author":"V Perfetti","year":"2006","unstructured":"Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica. 2006;91:1635\u201343.","journal-title":"Haematologica"},{"key":"1922_CR11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317\u201325.","journal-title":"Leukemia"},{"key":"1922_CR12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","volume":"87","author":"G Palladini","year":"2012","unstructured":"Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;87:465\u201371.","journal-title":"Am J Hematol"},{"key":"1922_CR13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bmt.1704691","volume":"34","author":"MA Gertz","year":"2004","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34:1025\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"1922_CR14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-014-1680-1","volume":"100","author":"T Hayashi","year":"2014","unstructured":"Hayashi T, Ikeda H, Igarashi T, Maruyama Y, Aoki Y, Nojima M, et al. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. Int J Hematol. 2014;100:554\u20138.","journal-title":"Int J Hematol"},{"key":"1922_CR15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2004.04970.x","volume":"125","author":"Guidelines Working Group of UK Myeloma Forum","year":"2004","unstructured":"Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125:681\u2013700.","journal-title":"Br J Haematol"},{"key":"1922_CR16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083\u201393.","journal-title":"N Engl J Med"},{"key":"1922_CR17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clml.2014.02.003","volume":"14","author":"EC Scott","year":"2014","unstructured":"Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, et al. Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leuk. 2014;14:424\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1922_CR18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","volume":"21","author":"V Sanchorawala","year":"2015","unstructured":"Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21:1445\u201351.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1922_CR19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","volume":"139","author":"AD Cohen","year":"2007","unstructured":"Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u00a0\u00b1\u00a0thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139:224\u201333.","journal-title":"Br J Haematol"},{"key":"1922_CR20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2012.274","volume":"27","author":"H Landau","year":"2013","unstructured":"Landau H, Hassoun H, Rosenzweig MA, Mauer M, Liu J, Flombaum C, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27:823\u20138.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1922-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1922-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1922-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:28Z","timestamp":1559452288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1922-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,24]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1922-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,24]]}}}